Dulanermin targets both TRIAL-R1/2 for colorectal cancer CRC and non-small cell lung cancer NSCLC, Mapatumumab target TRIAL-R1 for advanced solid tumors and NSCLC, PR095780 for Advanced solid tumors, NHL in I and II phase.71-76 Lexatumumab (HGS-ETR2) and Conatumumab (AMG-655) target TRIAL-R2 for Advanced solid tumors in I phase.77-80 Despite all the success of TRAIL targeted cancer therapy, TRAIL resistance is a common hindrance in TRAIL-based therapy that restricts the efficacy of these drugs.81 This evidence concerns the gene TNFSF10 and cancer.